This trial is active, not recruiting.

Condition bipolar depression
Sponsor Northwestern University
Collaborator University of Pittsburgh
Start date February 2014
End date December 2017
Trial size 91 participants
Trial identifier NCT02048995, PRO14010387


Objective. Bipolar Disorders (BD) are a major public health problem. The investigators still lack knowledge of the mechanisms which contribute to BD. Hence treatments are few and limited, and clinical decision making is less refined. Currently, the investigators are investigating the effects of midday bright light therapy for the treatment of bipolar depression (University of Pittsburgh IRB approved protocol titled Light Therapy for Bipolar Disorder, IRB#: PRO09020546). In this study, the investigators propose to investigate a possible biological mechanism which might explain response to light treatment in depressed bipolar patients.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective
Bipolar Depressed - are participants with Bipolar Disorder Type I or II and a current episode of major depression which is confirmed on the SCID interview
Healthy Comparator - are participants without mental disorders, alcohol or substance disorders confirmed by the SCID-interview

Primary Outcomes

visual evoked potentials (VEP) waveforms (mean amplitudes or latencies)
time frame: Week 0 and Week 6
Electroretinography (ERG) waveforms (mean amplitudes or latencies)
time frame: Week 0 and Week 6

Eligibility Criteria

All participants from 18 years up to 50 years old.

Inclusion Criteria: - Ages 18-50 years. - DSM-IV BD Type I or II, current major depressive episode - Stable-dosed antidepressant drug for 4 weeks or more only with concurrent antimanic drug. - Controlled thyroid disease. - Subjects with preexisting eye diseases will be included specific exceptions are described in the Exclusion Criteria. - Able to provide informed consent. - Stable minimum dose of antimanic drug for 4weeks or more. - Stable unchanged psychotherapy for 16 weeks or more. - Permitted drugs for sleep at low doses. Exclusion Criteria: - Certain specific eye diseases (retinal disease, untreated cataracts or macular degeneration) - Photosensitizing drugs such as phenothiazines (chlorpromazine), antimalarial drugs, melatonin and hypericum. - Acute psychosis (DSM-IV Criteria) - Rapid cycling in the past 1 year - Alcohol or substance abuse or dependence in the past 6 months. - Current symptoms of hypomania or mania i.e. ManiaRatingScale=5 - Recent history of a suicide attempt (3 months) or active suicidal ideation (SIGH-ADS item H11=2 or more) - Treatment with propranolol (Inderal), exogenous melatonin, chronic NSAIDS.

Additional Information

Official title Neural and Visual Responses to Light in Bipolar Disorder: A Novel Putative Biomarker
Principal investigator Dorothy Sit, M.D.
Description The study goal is to understand how the response to light therapy relates to changes in vision, brain function and improvement in bipolar symptoms. The aims are to investigate mood levels plus the eye and brain responses to visual contrast stimuli in healthy comparators (HC) and bipolar depressed patients. Study Design and Methods. Overview. The investigators plan to enroll 18-50 year old adults with BD Type I or II and a current episode of major depression on stable-dosed antimanic drugs, and age and sex-matched HC - without mental disorders. Depressed patients with BD will be assigned randomly to receive active light therapy vs inactive comparator for 6 weeks. The investigators will examine responses to contrast stimuli from measures of visual evoked potentials and electro-retinography in HC and depressed bipolar patients before and after 6-weeks of daily midday light therapy. The investigators will assess repeated measures of mood symptom levels, attention and circadian rhythms.
Trial information was received from ClinicalTrials.gov and was last updated in March 2017.
Information provided to ClinicalTrials.gov by Northwestern University.